Xiaosong Meng received his undergraduate degree in Electrical Engineering prior to starting the MD/PhD program at NYU. His PhD work under the guidance of James Salzer focused on studying how Schwann cells interact with axons to promote myelin formation in the peripheral nervous system. 

After graduating from medical school, he matched into Urology at NYU where he played a key role in building the NYU prostate MRI and MRI-US fusion-targeted prostate biopsy database which formed the basis for multiple projects throughout residency. He also gained significant experience with focal cryotherapy, which helped fuel his interest in focal therapy for prostate cancer. He then moved to Dallas where he completed his urologic oncology fellowship at UT Southwestern Medical Center. 

He is currently an assistant professor and Dedman Family Scholar in Clinical Care in the Department of Urology at UT Southwestern Medical Center and treats patients with a variety of urologic malignancies (kidney, bladder, prostate, testis and penile). He has a clinical focus on prostate cancer and prostate cancer focal therapy.  His affiliations include membership in the American Urological Association, the Endourological Society, the Focal Therapy Society, and the Society for Urologic Oncology. He offers robotic radical prostatectomy, transurethral ultrasound ablation (TULSA), and irreversible electroporation (IRE) as treatment options for patients with prostate cancer. Additionally, he offers transperineal prostate biopsies with the ExactVu micro-ultrasound platform. He is involved in multiple clinical trials at UTSW regarding prostate cancer including the CAPTAIN randomized clinical trial comparing surgery to ablation. His research focus involves methods of looking at cancer recurrence after focal therapy and optimizing patient selection for treatment.


Medical School
NYU School of Medicine (2014)
New York University School of Medicine (2015), General Surgery
New York University School of Medicine (2019), Urology


Featured Publications LegendFeatured Publications

Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
Meng X, Chao B, Chen F, Huang R, Taneja SS, Deng FM, J Urol 2021 Mar 205 3 748-754
Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
Feuer Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, Moore CM, Huang R, Deng FM, Lepor H, Wysock JS, Huang WC, Taneja SS, J Urol 2021 03 205 3 740-747
Robotic Nephroureterectomy vs. Laparoscopic Nephroureterectomy: Increased Utilization, Rates of Lymphadenectomy, Decreased Morbidity Robotically.
Kenigsberg A, Smith W, Meng X, Ghandour R, Rapoport L, Bagrodia A, Lotan Y, Woldu S, Margulis V, J Endourol 2020 Oct
Oncologic outcomes of radical nephroureterectomy (RNU).
Kenigsberg AP, Meng X, Ghandour R, Margulis V, Translational andrology and urology 2020 Aug 9 4 1841-1852
Real-World Application of Pre-orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management.
Badia RR, Abe D, Wong D, Singla N, Savelyeva A, Chertack N, Woldu SL, Lotan Y, Mauck R, Ouyang D, Meng X, Lewis CM, Majmudar K, Jia L, Kapur P, Xu L, Frazier AL, Margulis V, Strand DW, Coleman N, Murray MJ, Amatruda JF, Lafin JT, Bagrodia A, J. Urol. 2020 Aug 101097JU0000000000001337
Feasibility and Safety of Robotic Excision of Ipsilateral Retroperitoneal Recurrence after Nephrectomy for Renal Cell Carcinoma.
Ghandour R, Miranda AF, Singla N, Meng X, Enikeev D, Woldu S, Bagrodia A, Cadeddu J, Gahan J, Margulis V, Urology 2020 Aug
Overcoming sociodemographic factors in the care of patients with testicular cancer at a safety net hospital.
Chertack N, Ghandour RA, Singla N, Freifeld Y, Hutchinson RC, Courtney K, Bowman IA, Arafat W, Meng X, Moore JA, Aydin AM, Sagalowsky AI, Margulis V, Lotan Y, Woldu SL, Bagrodia A, Cancer 2020 Aug
Prospective evaluation of blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer.
Lotan Y, Chaplin I, Ahmadi H, Meng X, Roberts S, Ladi-Seyedian S, Bagrodia A, Margulis V, Woldu S, Daneshmand S, BJU Int. 2020 Jul
Does grossly complete transurethral resection improve response to neoadjuvant chemotherapy?
Ghandour RA, Kusin S, Wong D, Meng X, Singla N, Freifeld Y, Bagrodia A, Margulis V, Sagalowsky A, Lotan Y, Woldu SL, Urol. Oncol. 2020 Jul
Critical treatment choices for patients with platinum-refractory urothelial carcinoma.
Lotan Y, Meng X, Lancet Oncol. 2019 Nov